|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
11/9/2012 8:10:42 AM
EMD Millipore, a division of German pharmaceutical giant Merck, has laid off several staffers in St. Charles. The layoffs occurred within the bioscience business unit, and were the “result of the organization going through an evaluation of its functions, as well as the business environment and re-directing its focus to growth areas that fit the company’s long-term business strategy,” a company spokeswoman, Jennifer Bianco, said in an email message. She said the staff reduction affected “less than 2 percent” of the St. Charles headcount. EMD Millipore, with headquarters in Billerica, Mass., has 10,000 employees worldwide; it had 300 full-time employees in St. Charles as of this past spring, reported the St. Charles Economic Development Center, citing data from Dun & Bradstreet. Merck bought Millipore for $7.2 billion in cash in 2010. The St. Charles facility houses the company’s bioscience drug discovery headquarters and offers contract laboratory services. Before the acquisition by Merck, Millipore was a fast-growing company with big plans to grow jobs in St. Charles.
|
|
|
|
|
|
|
|
|
|
|